ReviewFrontiers in pediatrics2020
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis.
Review in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- 2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.Arquivos de neuro-psiquiatria · 2025Guideline
- Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.CNS drugs · 2026Review
- Article
- Seronegative Neuromyelitis Optica Spectrum Disorder in a Six-Year-Old Patient: A Case Report.Cureus · 2026Article
- AQP4+ NMOSD, MDA5+ Clinically Amyopathic Dermatomyositis and sHLH in a Pediatric Patient: A Case Report and Literature Review.Journal of inflammation research · 2026Article
- A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics.Pediatric radiology · 2025Review
- Confusing Onset of MOGAD in the Form of Focal Seizures.Neurology international · 2025Article
- Navigating Complexity in Pediatric NMOSD: Unusual Symptoms and Adverse Reactions: A Case Report.Reports (MDPI) · 2025Article
- Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease.Current neurology and neuroscience reports · 2024Review
- Advances in the long-term treatment of neuromyelitis optica spectrum disorder.Journal of central nervous system disease · 2024Review
- Case Report: Contiguous presentation of anti-MDA5 juvenile dermatomyositis and anti-AQP4 neuromyelitis optica spectrum disorder in an adolescent patient.Frontiers in pediatrics · 2024Article
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases.Pharmaceutics · 2023Article
- The Neutrophil-to-Lymphocyte Ratio and the Monocyte-to-Lymphocyte Ratio Predict Expanded Disability Status Scale Score at One Year in Pediatric Neuromyelitis Optica Spectrum Disorder but not in Multiple Sclerosis.Pediatric neurology · 2023Article
- Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.PharmacoEconomics - open · 2023Article
- Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents.Arquivos de neuro-psiquiatria · 2023Review
- Can early-onset acquired demyelinating syndrome (ADS) hide pediatric Behcet's disease? A case report.Frontiers in pediatrics · 2023Article
- Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.Journal of managed care & specialty pharmacy · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory demyelinating disease of the central nervous system (CNS) primarily affecting the optic nerves and spinal cord, but also involving other regions of the CNS including the area postrema, periaqueductal gray matter, and hypothalamus. Knowledge related to pediatric manifestations of NMOSD has grown in recent years, particularly in light of newer information regarding the importance of not only antibodies to aquaporin 4 (AQP4-IgG) but also myelin oligodendrocyte glycoprotein (MOG-IgG) in children manifesting clinically with this syndrome. In this review, we describe the current state of the knowledge related to clinical manifestations, diagnosis, and chronic therapies for children with NMOSD, with emphasis on literature that has been published in the last 5 years. Following the review, we propose recommendations for the assessment/follow up clinical care, and treatment of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.